Browse drugs

…M, Sutton E, Nesbit S, et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results fro…

…bo or pre–post studies) reporting significant results favouring metformin in 83.3% (30/36). A knowledge gap also exists for metformin use…

…QR: 4, 9 mg vs 2 mg, IQR: 2,6 mg, p = 0.04). Patients receiving ropivacaine used more morphine (8:00 p.m. on the first POD until 8:00 a.m. …

…ients with CHD with and without cirrhosis who were treated with BLV 2 mg for up to 144W reported improvements in their perceived he…

…t met all response criteria (ELF, LSM-VCTE, histology) was 16% (semaglutide) vs 5.6% (pla-cebo).The incidence of serious adverse events in …

…Elafibranor is a dual PPAR-α/δ agonist recently licenced for treatment of P…

…reatment.Of the five patients, four were treated with off-label Timolol. Two achieved complete symptom resolution within eight weeks an…

…ors associated with PACS and MVD. The discriminatory ability of sdLDL-C for PACS with MVD was assessed using receiver operating charact…

…pact on bone health in diabetes.31 To this end, serum levels of pentosidine have been associated with prevalent fractures in T1D independen…

… and without a diagnosis of POAG prior to diabetes diagnosis or metformin use. Bivariate logistic regression, multivariable logistic regr…

… to understand the subset of volunteers that benefited from the Intralipid® 20% reversal. This method may shorten the LA effects in a clinical …

…ect of 5-HIAA on tumor-infiltrating lymphocytes. The effects of phenelzine (Phe) and Akkermansia muciniphila (AKK) on 5-HIAA synthesis, an…